Hua Medicine (Shanghai) Ltd. operates as a clinical-stage drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin that is in Phase I clinical trial for treatment of T2D. The company also offers Dorzagliatin in combination with Pioglitazone for NASH; in combination with GLP-1 for Alzheimer diseases; and in combination with late stage T2D and Type 1 Diabetes. In addition, it is developing mGLUR5 for the treatment of Parkinson's disease levodopa-induced dyskinesia. The company was incorporated in 2011 and is based in Beijing, China.
Show more...
FAQ
Hua Medicine 今天的股價是多少?▼
2552.HK 目前價格為 HK$3.58 HKD,過去 24 小時下跌了 -1.38%。在圖表上更密切關注 Hua Medicine 股票的表現。
Hua Medicine 的股票代號是什麼?▼
根據交易所不同,股票代號可能會有所差異。例如,在 交易所,Hua Medicine 的股票以代號 2552.HK 進行交易。
Hua Medicine 的股價在上漲嗎?▼
2552.HK 股票較上週下跌 -7.01%,本月上漲 +15.48%,過去一年 Hua Medicine 上漲 +79.9%。
Hua Medicine 的市值是多少?▼
今天 Hua Medicine 的市值為 3.78B
Hua Medicine 下一次財報日期是什麼時候?▼
Hua Medicine 將於 August 20, 2026 公布下一次財報。
Hua Medicine 去年的營收是多少?▼
Hua Medicine 去年的營收為 545.82MHKD。
Hua Medicine 去年的淨利是多少?▼
2552.HK 去年的淨收益為 -533.98MHKD。
Hua Medicine 有多少名員工?▼
截至 April 22, 2026,公司共有 147 名員工。
Hua Medicine 位於哪個產業?▼
Hua Medicine從事於Health & Wellness產業。
Hua Medicine 何時完成拆股?▼
Hua Medicine 最近沒有進行任何拆股。
Hua Medicine 的總部在哪裡?▼
Hua Medicine 的總部位於 香港 的 Beijing。